The U.S. peptide therapeutics retail market is experiencing strong growth as peptide-based medicines become increasingly important in the treatment of diabetes, obesity, weight management, hormone-related conditions, and other chronic diseases. Growing use of GLP-1 receptor agonists, expanding patient awareness, and increasing availability through retail pharmacies and telehealth platforms are reshaping how peptide therapies reach patients. Medications such as semaglutide and tirzepatide have strengthened demand, while innovations including once-weekly injections, oral peptide formulations, and newer multi-agonist therapies are improving convenience. Traditional pharmacy chains are also being complemented by online pharmacies and direct-to-consumer healthcare platforms, creating a more accessible and consumer-focused distribution environment.

Key Market Projections (2026–2033)

The U.S. peptide therapeutics retail side market was valued at USD 103.66 billion in 2024 and is expected to reach USD 336.12 billion by 2033, expanding at a CAGR of 12.77% from 2025 to 2033. The market is being supported by the rising prevalence of chronic diseases, increasing demand for peptide-based treatments, and the expansion of retail and telehealth distribution channels.

One of the strongest contributors to market growth is the increasing use of GLP-1 therapies. Spending on GLP-1 therapies in the U.S. increased from USD 13.7 billion in 2018 to more than USD 71.7 billion in 2023, with retail pharmacies accounting for more than 70% of this increase. In 2024, tirzepatide's Zepbound generated USD 4.9 billion in sales, while Wegovy and Saxenda together generated USD 9.9 billion.

The market is also benefiting from improvements in peptide formulations and delivery methods. FDA approvals involving dual agonists, once-weekly injectable therapies, oral peptide medicines, and emerging generic and biosimilar options are expanding treatment choices while reducing administration burdens for patients.

Download a free sample copy of the U.S. Peptide Therapeutics market report to understand detailed coverage and inclusions in the final report

Core Drivers and Technology Trends

The increasing prevalence of obesity and type 2 diabetes is one of the primary factors driving demand for peptide therapeutics. GLP-1 receptor agonists such as semaglutide and liraglutide provide both glycemic control and weight management benefits, increasing their adoption among patients and healthcare providers. Expanding indications and greater recognition of obesity as a chronic condition are also broadening the potential patient population.

Patient convenience is another important market driver. Traditional peptide therapies have often relied on injectable administration because peptides can be unstable in the gastrointestinal tract. However, pharmaceutical companies are increasingly developing oral, nasal, and longer-acting formulations. These innovations can reduce administration frequency and improve adherence, particularly for patients requiring long-term treatment.

Once-weekly therapies represent an important development. The introduction of longer-acting peptide medicines provides an alternative to daily administration and can simplify treatment routines. Oral peptide products are also creating opportunities for patients who prefer non-injectable options.

Digital healthcare is transforming access to peptide therapies. Telehealth providers can combine virtual consultations, prescription services, pharmacy fulfillment, follow-up support, and home delivery. Companies such as LillyDirect, Ro, Hims & Hers, and Amazon Pharmacy are contributing to the expansion of consumer-oriented peptide therapy channels.

At the same time, pricing and regulatory requirements remain important market considerations. FDA oversight, manufacturing standards, insurance coverage, and differences between branded, generic, biosimilar, and compounded products can influence affordability and availability. The high retail prices of some FDA-approved peptide medicines without insurance can also affect patient access.

Segment and Regional Breakdown

• The market is segmented by peptide type, therapeutics type, indication, route of administration, and distribution channel. Since the report focuses specifically on the U.S., regional analysis is centered on the national retail ecosystem and its pharmacy, telehealth, and specialized clinic channels.
• By peptide type, GLP-1 peptides dominated the market in 2024 with a 43.32% share and are expected to record the fastest CAGR during the forecast period. The segment benefits from increasing demand for treatments addressing diabetes and obesity, along with continued innovation in GLP-1-based therapies.
• The wellness, longevity, and healthspan peptides segment is also expected to grow significantly. Interest in healthy aging, preventive healthcare, personalized medicine, and longevity is increasing demand for peptide-based interventions positioned around metabolic health, immune function, muscle preservation, and other wellness applications.
• By therapeutics type, innovative branded peptides held more than 43.52% of the market in 2024. Branded products benefit from clinical differentiation, established regulatory approvals, intellectual property protection, and specialized delivery technologies. Biosimilar peptides are expected to experience significant growth as manufacturers pursue alternatives to established peptide therapies and seek to broaden treatment accessibility.
• By indication, type 2 diabetes accounted for more than 25.79% of the market in 2024. The segment is supported by widespread use of GLP-1 receptor agonists and the chronic nature of diabetes treatment, which creates recurring demand through retail pharmacies. The obesity and weight management segment is expected to grow significantly as peptide therapies gain wider clinical recognition and patient acceptance.
• By route of administration, parenteral therapies held more than 33.31% of the market in 2024. Injectable administration remains important because it provides reliable delivery and high bioavailability for peptide medicines. However, nasal and oral approaches are gaining attention as pharmaceutical companies work to develop more convenient delivery options.
• By distribution channel, offline retail pharmacies held a 38.51% share in 2024. Chain pharmacies, specialty pharmacies, and independent community pharmacies remain important because they provide pharmacist interaction, prescription fulfillment, and medication support. Online pharmacies and telehealth platforms are expected to expand significantly because of mail-order delivery, automated refills, digital consultations, and pricing transparency.

Looking for more specific insights? Customize this report to suite your business needs

Spot Emerging 2026 Trends

In 2026, the U.S. peptide therapeutics retail market is increasingly moving toward convenient, consumer-focused, and digitally supported treatment models. GLP-1 therapies are expected to remain a major growth engine, while next-generation therapies and combination approaches continue expanding the treatment landscape.

The development of oral peptide medicines is an important emerging trend. Oral delivery could reduce injection-related barriers and increase convenience for patients requiring long-term therapy. Nasal delivery is also attracting attention because it can provide a non-invasive route and may offer opportunities for therapies targeting neurological conditions.

Telehealth-enabled peptide distribution is another major trend. Online platforms are combining physician consultations, prescription fulfillment, medication delivery, and ongoing patient support into integrated services. This model is particularly relevant for chronic conditions requiring repeat prescriptions.

Retail pharmacies are also becoming more integrated with clinical support programs. In May 2025, Evernorth announced the expansion of its GLP-1 care model through EnReachRx, integrating retail pharmacies with clinical support that includes patient education, dose optimization, and adherence assistance.

Competition is also expanding beyond traditional pharmacy chains. The market includes established retailers such as CVS Health, Walgreens, Walmart Pharmacy, Kroger, Albertsons, Publix, Costco, and Meijer, alongside online providers including Hims & Hers, Ro, Amazon, GoodRx, Honeybee Health, and AgelessRx. Specialized hormone and longevity clinics are creating another distribution channel for peptide-based therapies.

In February 2025, Hims & Hers acquired a U.S.-based peptide production facility in California to strengthen domestic supply capabilities and support consistent delivery of personalized peptide-based medications. Such developments demonstrate the growing importance of supply chain control and vertically integrated healthcare models.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.